Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross

Achieng, 2015, Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya, Int. J. Parasitol. Drugs Drug Resist., 5, 92, 10.1016/j.ijpddr.2015.05.005 Amambua-Ngwa, 2017, Sustained ex vivo susceptibility of Plasmodium falciparum to artemisinin derivatives but increasing tolerance to artemisinin combination therapy partner quinolines in the Gambia, Antimicrob. Agents Chemother., 61, 10.1128/AAC.00759-17 Amaratunga, 2014, Flow cytometry-based analysis of artemisinin-resistant Plasmodium falciparum in the ring-stage survival assay, Antimicrob. Agents Chemother., 58, 4938, 10.1128/AAC.02902-14 Baliraine, 2011, Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda, J. Infect. Dis., 204, 1120, 10.1093/infdis/jir486 Baraka, 2015, In vivo selection of Plasmodium falciparum pfcrt and pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso, Antimicrob. Agents Chemother., 59, 734, 10.1128/AAC.03647-14 Basco, 1998, In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon, Antimicrob. Agents Chemother., 42, 2347, 10.1128/AAC.42.9.2347 Basco, 2007, Molecular epidemiology of malaria in Cameroon. XXIV. Trends of in vitro antimalarial drug responses in Yaounde, Cameroon, Am. J. Trop. Med. Hyg., 76, 20, 10.4269/ajtmh.2007.76.20 Birnbaum, 2020, A Kelch13-defined endocytosis pathway mediates artemisinin resistance in malaria parasites, Science, 367, 51, 10.1126/science.aax4735 Bloom, 2013, Finding the sources of missing heritability in a yeast cross, Nature, 494, 234, 10.1038/nature11867 Broman, 2003, R/qtl: QTL mapping in experimental crosses, Bioinformatics, 19, 889, 10.1093/bioinformatics/btg112 Challenger, 2017, Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling, Nat. Commun., 8, 1373, 10.1038/s41467-017-01352-3 Chavchich, 2016, The spiroindolone KAE609 does not induce dormant ring stages in Plasmodium falciparum parasites, Antimicrob. Agents Chemother., 60, 5167, 10.1128/AAC.02838-15 Combrinck, 2013, Insights into the role of heme in the mechanism of action of antimalarials, ACS Chem. Biol., 8, 133, 10.1021/cb300454t Conrad, 2014, Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children, J. Infect. Dis., 210, 344, 10.1093/infdis/jiu141 Cooper, 2002, Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum, Mol. Pharmacol., 61, 35, 10.1124/mol.61.1.35 Cowman, 1991, A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole, J. Cell Biol., 113, 1033, 10.1083/jcb.113.5.1033 Cranmer, 1997, An alternative to serum for cultivation of Plasmodium falciparum in vitro, Trans. R. Soc. Trop. Med. Hyg., 91, 363, 10.1016/S0035-9203(97)90110-3 Dama, 2017, Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether-lumefantrine treatment in Mali, Malar. J., 16, 59, 10.1186/s12936-017-1700-8 de Koning-Ward, 2015, Advances in molecular genetic systems in malaria, Nat. Rev. Microbiol., 13, 373, 10.1038/nrmicro3450 Denis, 2006, Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia, Trop. Med. Int. Health, 11, 1800, 10.1111/j.1365-3156.2006.01739.x Dhingra, 2019, Global spread of mutant PfCRT and its pleiotropic impact on Plasmodium falciparum multidrug resistance and fitness, mBio, 10, 10.1128/mBio.02731-18 Dokomajilar, 2006, Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic, Antimicrob. Agents Chemother., 50, 1893, 10.1128/AAC.50.5.1893-1895.2006 Duraisingh, 2000, Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum, Mol. Microbiol., 36, 955, 10.1046/j.1365-2958.2000.01914.x Eyase, 2013, The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011, PloS One, 8, 10.1371/journal.pone.0064299 Farnert, 2012, Artemether-lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania, Malar. J., 11, 176, 10.1186/1475-2875-11-176 Fidock, 2000, Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance, Mol. Cell., 6, 861, 10.1016/S1097-2765(05)00077-8 Figan, 2018, A set of microsatellite markers to differentiate Plasmodium falciparum progeny of four genetic crosses, Malar. J., 17, 60, 10.1186/s12936-018-2210-z Foote, 1990, Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum, Nature, 345, 255, 10.1038/345255a0 Gadalla, 2011, Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine, Antimicrob. Agents Chemother., 55, 5408, 10.1128/AAC.05102-11 Garimella, 2020, Detection of simple and complex de novo mutations with multiple reference sequences, Genome Res., 30, 1154, 10.1101/gr.255505.119 Happi, 2009, Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria, Antimicrob. Agents Chemother., 53, 888, 10.1128/AAC.00968-08 Harding, 2020, Genetic screens reveal a central role for heme metabolism in artemisinin susceptibility, Nat. Commun., 11, 4813, 10.1038/s41467-020-18624-0 Hayton, 2008, Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion, Cell Host Microbe, 4, 40, 10.1016/j.chom.2008.06.001 Humphreys, 2007, Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria, Antimicrob. Agents Chemother., 51, 991, 10.1128/AAC.00875-06 Lambros, 1979, Synchronization of Plasmodium falciparum erythrocytic stages in culture, J. Parasitol., 65, 418, 10.2307/3280287 Lane, 2018, Selection of Plasmodium falciparum cytochrome B mutants by putative PfNDH2 inhibitors, Proc. Natl. Acad. Sci. U. S. A., 115, 6285, 10.1073/pnas.1804492115 Lekana-Douki, 2011, Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine, Infect. Genet. Evol., 11, 512, 10.1016/j.meegid.2011.01.003 Li, 2014, High prevalence of pfmdr1 N86Y and Y184F mutations in Plasmodium falciparum isolates from Bioko Island, Equatorial Guinea, Pathog. Glob. Health, 108, 339, 10.1179/2047773214Y.0000000158 Makanga, 2009, The clinical efficacy of artemether/lumefantrine (Coartem), Malar. J., 8, S5, 10.1186/1475-2875-8-S1-S5 Malmberg, 2013, Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms, J. Infect. Dis., 207, 842, 10.1093/infdis/jis747 Molina-Cruz, 2013, The human malaria parasite Pfs47 gene mediates evasion of the mosquito immune system, Science, 340, 984, 10.1126/science.1235264 Mwai, 2009, In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1, Antimicrob. Agents Chemother., 53, 5069, 10.1128/AAC.00638-09 Nair, 2007, Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites, Mol. Biol. Evol., 24, 562, 10.1093/molbev/msl185 Nguitragool, 2011, Malaria parasite clag3 genes determine channel-mediated nutrient uptake by infected red blood cells, Cell, 145, 665, 10.1016/j.cell.2011.05.002 Nsobya, 2010, In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda, Antimicrob. Agents Chemother., 54, 1200, 10.1128/AAC.01412-09 Nzila, 2012, Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine, J. Antimicrob. Chemother., 67, 2309, 10.1093/jac/dks252 Oduola, 1993, Reversal of mefloquine resistance with penfluridol in isolates of Plasmodium falciparum from south-west Nigeria, Trans. R. Soc. Trop. Med. Hyg., 87, 81, 10.1016/0035-9203(93)90434-R Okombo, 2014, Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya, Int J Parasitol Drugs Drug Resist, 4, 152, 10.1016/j.ijpddr.2014.07.003 Peterson, 1990, Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria, Proc. Natl. Acad. Sci. U. S. A., 87, 3018, 10.1073/pnas.87.8.3018 Peterson, 1988, Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria, Proc. Natl. Acad. Sci. U. S. A., 85, 9114, 10.1073/pnas.85.23.9114 Phillips, 2017, Malaria, Nat. Rev. Dis. Primers, 3, 10.1038/nrdp.2017.50 Phyo, 2016, Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): the role of parasite genetic factors, Clin. Infect. Dis., 63, 784, 10.1093/cid/ciw388 Pradines, 2006, Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo, J. Clin. Microbiol., 44, 2404, 10.1128/JCM.00623-06 Pradines, 1999, In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs, Antimicrob. Agents Chemother., 43, 418, 10.1128/AAC.43.2.418 Premji, 2009, Coartem: the journey to the clinic, Malar. J., 8, S3, 10.1186/1475-2875-8-S1-S3 Price, 2006, Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria, Clin. Infect. Dis., 42, 1570, 10.1086/503423 Sá, 2018, Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model, Proc. Natl. Acad. Sci. U. S. A., 115, 12513, 10.1073/pnas.1813386115 Sá, 2019, Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross, Nat. Commun., 10, 4300, 10.1038/s41467-019-12256-9 Sá, 2009, Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine, Proc. Natl. Acad. Sci. U. S. A., 106, 18883, 10.1073/pnas.0911317106 Sidhu, 2006, Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin, J. Infect. Dis., 194, 528, 10.1086/507115 Sisowath, 2007, The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa, Trop. Med. Int. Health, 12, 736, 10.1111/j.1365-3156.2007.01843.x Sisowath, 2009, In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa, J. Infect. Dis., 199, 750, 10.1086/596738 Sisowath, 2005, In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem), J. Infect. Dis., 191, 1014, 10.1086/427997 Smilkstein, 2004, Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening, Antimicrob. Agents Chemother., 48, 1803, 10.1128/AAC.48.5.1803-1806.2004 Somé, 2010, Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso, Antimicrob. Agents Chemother., 54, 1949, 10.1128/AAC.01413-09 Sonden, 2017, High rate of treatment failures in nonimmune travelers treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Sweden: retrospective comparative analysis of effectiveness and case series, Clin. Infect. Dis., 64, 199, 10.1093/cid/ciw710 Sondo, 2016, Artesunate-amodiaquine and artemether-lumefantrine therapies and selection of pfcrt and pfmdr1 alleles in Nanoro, Burkina Faso, PloS One, 11, 10.1371/journal.pone.0151565 Valecha, 2012, Efficacy of artemether-lumefantrine in area of high malaria endemicity in India and its correlation with blood concentration of lumefantrine, Am. J. Trop. Med. Hyg., 86, 395, 10.4269/ajtmh.2012.11-0182 Vaughan, 2015, Plasmodium falciparum genetic crosses in a humanized mouse model, Nat. Methods, 12, 631, 10.1038/nmeth.3432 Veiga, 2016, Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies, Nat. Commun., 7, 11553, 10.1038/ncomms11553 Vendrely, 2020, Humanized mice and the rebirth of malaria genetic crosses, Trends Parasitol., 36, 850, 10.1016/j.pt.2020.07.009 Venkatesan, 2014, Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine, Am. J. Trop. Med. Hyg., 91, 833, 10.4269/ajtmh.14-0031 Wang, 1997, Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization, Mol. Microbiol., 23, 979, 10.1046/j.1365-2958.1997.2821646.x Wellems, 1991, Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7, Proc. Natl. Acad. Sci. U. S. A., 88, 3382, 10.1073/pnas.88.8.3382 White, 1999, Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine, Clin. Pharmacokinet., 37, 105, 10.2165/00003088-199937020-00002 2015 2019 Wurtz, 2014, Role of pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin, Antimicrob. Agents Chemother., 58, 7032, 10.1128/AAC.03494-14 Yang, 2019, Decreased K13 abundance reduces hemoglobin catabolism and proteotoxic stress, underpinning artemisinin resistance, Cell Rep., 29, 2917, 10.1016/j.celrep.2019.10.095 Zongo, 2007, Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial, Lancet, 369, 491, 10.1016/S0140-6736(07)60236-0